ArticleBioengineered2022

Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro.

Jingquan Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.